Rivals will team up in order to accelerate supply
Merck & Co. will help manufacture Johnson & Johnson’s recently approved coronavirus vaccine to grow supply more quickly, President Joe Biden announced earlier today, several news outlets reported.
According to the Associated Press, the news comes as the White House looks to accelerate production of the single-dose vaccine. Officials have noted that J&J faced unexpected production issues with its vaccine, producing only 3.9 million doses ahead of it receiving emergency use authorization (EUA) over the weekend. The company says it expects to deliver 100 million doses by the end of June.
White House press secretary Jen Psaki also announced today that the federal government was increasing supply of vaccines to states next week to 15.2 million doses per week, up from 14.5 million previously. States will also receive 2.8 million doses of the J&J shot this week.
Stay ahead in the life sciences industry with Pharmaceutical Commerce, the latest news, trends, and strategies in drug distribution, commercialization, and market access.
Multi-Indication Drug Branding in Today’s Pharmaceutical Industry
July 2nd 2025As drug development increasingly targets multiple indications, pharma companies must make strategic branding decisions—balancing regulatory requirements, market dynamics, and patient safety—to choose between single-brand or multi-brand approaches.